45 related articles for article (PubMed ID: 38723164)
1. A novel selenium nanocomposite modified by AANL inhibits tumor growth by upregulating CLK2 in lung cancer.
Zhang Y; Chen Y; Wang B; Cai Y; Zhang M; Guo X; Wu A; Wang W; Liu N; Wang X; Gong Y; Pan J; Jin Y
Bioorg Chem; 2024 Jul; 148():107459. PubMed ID: 38761707
[TBL] [Abstract][Full Text] [Related]
2. Discovery of potent CSK inhibitors through integrated virtual screening and molecular dynamic simulation.
Chen R; Wang Y; Shen Z; Ye C; Guo Y; Lu Y; Ding J; Dong X; Xu D; Zheng X
Arch Pharm (Weinheim); 2024 May; ():e2400066. PubMed ID: 38809025
[TBL] [Abstract][Full Text] [Related]
3. In silico identification of a novel Cdc2-like kinase 2 (CLK2) inhibitor in triple negative breast cancer.
Huang CC; Hsu CM; Chao MW; Hsu KC; Lin TE; Yen SC; Tu HJ; Pan SL
Protein Sci; 2024 Jun; 33(6):e5004. PubMed ID: 38723164
[TBL] [Abstract][Full Text] [Related]
4. Development of MPS1 Inhibitors: Recent Advances and Perspectives.
Zeng Y; Ren X; Jin P; Zhang Y; Zhuo M; Wang J
J Med Chem; 2023 Dec; 66(24):16484-16514. PubMed ID: 38095579
[TBL] [Abstract][Full Text] [Related]
5. Transcriptome reprogramming through alternative splicing triggered by apigenin drives cell death in triple-negative breast cancer.
Sudhakaran M; Navarrete TG; Mejía-Guerra K; Mukundi E; Eubank TD; Grotewold E; Arango D; Doseff AI
Cell Death Dis; 2023 Dec; 14(12):824. PubMed ID: 38092740
[TBL] [Abstract][Full Text] [Related]
6. Exploring the roles of the Cdc2-like kinases in cancers.
Blackie AC; Foley DJ
Bioorg Med Chem; 2022 Sep; 70():116914. PubMed ID: 35872347
[TBL] [Abstract][Full Text] [Related]
7. A critical update on the strategies towards small molecule inhibitors targeting Serine/arginine-rich (SR) proteins and Serine/arginine-rich proteins related kinases in alternative splicing.
Tang J; Xie Y; Huang J; Zhang L; Jiang W; Li Z; Bian J
Bioorg Med Chem; 2022 Sep; 70():116921. PubMed ID: 35863237
[TBL] [Abstract][Full Text] [Related]
8. Survival, treatment regimens and medical costs of women newly diagnosed with metastatic triple-negative breast cancer.
Hsu JY; Chang CJ; Cheng JS
Sci Rep; 2022 Jan; 12(1):729. PubMed ID: 35031634
[TBL] [Abstract][Full Text] [Related]
9. Alternative RNA splicing in tumour heterogeneity, plasticity and therapy.
Öther-Gee Pohl S; Myant KB
Dis Model Mech; 2022 Jan; 15(1):. PubMed ID: 35014671
[TBL] [Abstract][Full Text] [Related]
10. Targeting Splicing Factor SRSF6 for Cancer Therapy.
She W; Shao J; Jia R
Front Cell Dev Biol; 2021; 9():780023. PubMed ID: 34917618
[TBL] [Abstract][Full Text] [Related]
11. Development of Cdc2-like Kinase 2 Inhibitors: Achievements and Future Directions.
Qin Z; Qin L; Feng X; Li Z; Bian J
J Med Chem; 2021 Sep; 64(18):13191-13211. PubMed ID: 34519506
[TBL] [Abstract][Full Text] [Related]
12. Trends in kinase drug discovery: targets, indications and inhibitor design.
Attwood MM; Fabbro D; Sokolov AV; Knapp S; Schiöth HB
Nat Rev Drug Discov; 2021 Nov; 20(11):839-861. PubMed ID: 34354255
[TBL] [Abstract][Full Text] [Related]
13. Current Triple-Negative Breast Cancer Subtypes: Dissecting the Most Aggressive Form of Breast Cancer.
Ensenyat-Mendez M; Llinàs-Arias P; Orozco JIJ; Íñiguez-Muñoz S; Salomon MP; Sesé B; DiNome ML; Marzese DM
Front Oncol; 2021; 11():681476. PubMed ID: 34221999
[TBL] [Abstract][Full Text] [Related]
14. Splicing factor SRSF1 promotes breast cancer progression via oncogenic splice switching of PTPMT1.
Du JX; Luo YH; Zhang SJ; Wang B; Chen C; Zhu GQ; Zhu P; Cai CZ; Wan JL; Cai JL; Chen SP; Dai Z; Zhu W
J Exp Clin Cancer Res; 2021 May; 40(1):171. PubMed ID: 33992102
[TBL] [Abstract][Full Text] [Related]
15. The Functional Impact of Alternative Splicing on the Survival Prognosis of Triple-Negative Breast Cancer.
Wu S; Wang J; Zhu X; Chyr J; Zhou X; Wu X; Huang L
Front Genet; 2020; 11():604262. PubMed ID: 33519909
[TBL] [Abstract][Full Text] [Related]
16. SM04755, a small-molecule inhibitor of the Wnt pathway, as a potential topical treatment for tendinopathy.
Deshmukh V; Seo T; O'Green AL; Ibanez M; Hofilena B; Kc S; Stewart J; Dellamary L; Chiu K; Ghias A; Barroga C; Kennedy S; Tambiah J; Hood J; Yazici Y
J Orthop Res; 2021 Sep; 39(9):2048-2061. PubMed ID: 33104243
[TBL] [Abstract][Full Text] [Related]
17. Serine/arginine-rich splicing factors: the bridge linking alternative splicing and cancer.
Zheng X; Peng Q; Wang L; Zhang X; Huang L; Wang J; Qin Z
Int J Biol Sci; 2020; 16(13):2442-2453. PubMed ID: 32760211
[TBL] [Abstract][Full Text] [Related]
18. Comprehensive analysis and establishment of a prediction model of alternative splicing events reveal the prognostic predictor and immune microenvironment signatures in triple negative breast cancer.
Yu S; Hu C; Liu L; Cai L; Du X; Yu Q; Lin F; Zhao J; Zhao Y; Zhang C; Liu X; Li W
J Transl Med; 2020 Jul; 18(1):286. PubMed ID: 32723333
[TBL] [Abstract][Full Text] [Related]
19.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
